Regeneron Pharmaceuticals ((REGN)), Sanofi SA ((SNY)), Sanofi ((DE:SNW)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Regeneron Pharmaceuticals and Sanofi have announced a clinical study titled A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Longterm Safety of Dupilumab in Children 2 to <6 Years of Age With Uncontrolled Asthma and/or Recurrent Severe Asthmatic Wheeze. The study aims to evaluate the effectiveness and safety of Dupilumab in young children with uncontrolled asthma or severe asthmatic wheeze, highlighting its potential significance in pediatric asthma treatment.
The study tests Dupilumab, a subcutaneous injection, against a placebo. Dupilumab is designed to treat asthma by targeting specific pathways involved in the inflammatory process.
This Phase 3 study is interventional and randomized, employing a parallel assignment model with triple masking. Its primary purpose is treatment, ensuring a robust evaluation of Dupilumab’s efficacy and safety.
The study began on January 3, 2024, with primary completion expected in 2025. The last update was submitted on June 24, 2025, indicating ongoing progress and commitment to the study’s objectives.
The study’s results could significantly impact the stock performance of Regeneron and Sanofi, as positive outcomes may enhance investor sentiment and position the companies favorably against competitors in the pediatric asthma treatment market.
The study is currently ongoing, with further details available on the ClinicalTrials portal.